Castleark Management LLC Increases Stock Holdings in Elanco Animal Health Incorporated $ELAN

Castleark Management LLC boosted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 931.4% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 355,950 shares of the company’s stock after buying an additional 321,440 shares during the quarter. Castleark Management LLC’s holdings in Elanco Animal Health were worth $8,518,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. NewEdge Advisors LLC increased its position in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after acquiring an additional 627 shares during the last quarter. Root Financial Partners LLC lifted its holdings in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after acquiring an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. bought a new stake in shares of Elanco Animal Health in the 4th quarter worth about $41,000. Torren Management LLC purchased a new position in shares of Elanco Animal Health during the 4th quarter worth about $46,000. Finally, Bessemer Group Inc. boosted its stake in shares of Elanco Animal Health by 33.2% during the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after purchasing an additional 525 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Jeffrey N. Simmons bought 4,971 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The shares were acquired at an average cost of $20.09 per share, with a total value of $99,867.39. Following the completion of the transaction, the chief executive officer owned 171,971 shares in the company, valued at $3,454,897.39. The trade was a 2.98% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Rajeev A. Modi purchased 4,911 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were bought at an average cost of $20.35 per share, with a total value of $99,938.85. Following the purchase, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This represents a 3.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 1.14% of the company’s stock.

Analyst Ratings Changes

ELAN has been the topic of several analyst reports. JPMorgan Chase & Co. upped their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Citigroup upped their target price on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Morgan Stanley increased their price target on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. Finally, Weiss Ratings lowered Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Elanco Animal Health presently has an average rating of “Moderate Buy” and a consensus target price of $28.73.

Elanco Animal Health Trading Down 0.0%

NYSE ELAN opened at $24.90 on Monday. The stock has a market cap of $12.44 billion, a PE ratio of -49.80, a PEG ratio of 1.63 and a beta of 1.68. Elanco Animal Health Incorporated has a 12 month low of $13.39 and a 12 month high of $27.72. The company’s 50-day moving average price is $24.01 and its 200-day moving average price is $23.98. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The firm’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same quarter last year, the business posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Equities research analysts forecast that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.